Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Entrada Therapeutics Inc (TRDA)

Entrada Therapeutics Inc (TRDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Author
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings MarketBeat - Thu May 18, 2023

Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets.

VRTX : 468.00 (-0.12%)
CRSP : 44.62 (-1.39%)
TRDA : 14.80 (-3.83%)
MRNA : 72.89 (-0.75%)
GILD : 78.72 (-0.06%)
AMGN : 320.56 (-1.17%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA PR Newswire - Mon Feb 6, 2023

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA). Such...

TRDA : 14.80 (-3.83%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA PR Newswire - Wed Jan 4, 2023

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA). Such...

TRDA : 14.80 (-3.83%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA PR Newswire - Mon Dec 26, 2022

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA). Such...

TRDA : 14.80 (-3.83%)
Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1) Business Wire - Thu Dec 8, 2022

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced a global collaboration focused on discovering and developing intracellular Endosomal...

VRTX : 468.00 (-0.12%)
TRDA : 14.80 (-3.83%)
Entrada Therapeutics Reports Second Quarter 2022 Financial Results Globe Newswire - Thu Aug 11, 2022

On track to submit Investigational New Drug application to the U.S. Food and Drug Administration for ENTR-601-44 targeting Duchenne muscular dystrophy in...

TRDA : 14.80 (-3.83%)
Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer Globe Newswire - Tue Jul 19, 2022

BOSTON, July 19, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of...

TRDA : 14.80 (-3.83%)
Entrada Therapeutics to Present at William Blair Biotech Focus Conference Globe Newswire - Wed Jul 6, 2022

BOSTON, July 06, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of...

TRDA : 14.80 (-3.83%)
Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference Globe Newswire - Wed Jun 1, 2022

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of...

TRDA : 14.80 (-3.83%)
Entrada Therapeutics Reports First Quarter 2022 Financial Results Globe Newswire - Thu May 12, 2022

Second clinical candidate, ENTR-701, announced for the potential treatment of myotonic dystrophy type 1 On track to submit Investigational New Drug...

TRDA : 14.80 (-3.83%)

Barchart Exclusives

1 Breakout Growth Stock With 94% Upside Potential Barchart - Sat Sep 7, 11:15AM CDT
This breakout growth stock has already nearly doubled in value this year, but analysts see much more upside potential ahead as the space company locks down NASA contracts. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot